Affordable Access

deepdyve-link
Publisher Website

Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis.

Authors
  • Pal, Rimesh1
  • Banerjee, Mainak2
  • Yadav, Urmila3
  • Bhattacharjee, Sukrita4
  • 1 Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India [email protected] , (India)
  • 2 Internal Medicine, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India. , (India)
  • 3 National Institute of Nursing Education, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India. , (India)
  • 4 Department of Hematology, Institute of Hematology and Transfusion Medicine, Medical College and Hospital Kolkata, Kolkata, West Bengal, India. , (India)
Type
Published Article
Journal
Postgraduate Medical Journal
Publisher
BMJ
Publication Date
May 01, 2022
Volume
98
Issue
1159
Pages
354–359
Identifiers
DOI: 10.1136/postgradmedj-2020-139172
PMID: 33541927
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Observations studies have shown that prior use of statins is associated with a reduced risk of adverse clinical outcomes in patients with COVID-19. However, the available data are limited, inconsistent and conflicting. Besides, no randomised controlled trial exists in this regard. Hence, the present meta-analysis was conducted to provide an updated summary and collate the effect of statin use on clinical outcomes in COVID-19 using unadjusted and adjusted risk estimates. PubMed, Scopus and Web of Science databases were systematically searched using appropriate keywords till December 18 2020, to identify observational studies reporting clinical outcomes in COVID-19 patients using statins versus those not using statins. Prior and in-hospital use of statins were considered. Study quality was assessed using the Newcastle-Ottawa Scale. Unadjusted and adjusted pooled odds ratio (OR) with 95% CIs were calculated. We included 14 observational studies pooling data retrieved from 19 988 patients with COVID-19. All the studies were of high/moderate quality. Pooled analysis of unadjusted data showed that statin use was not associated with improved clinical outcomes (OR 1.02; 95% CI 0.69 to 1.50, p=0.94, I2=94%, random-effects model). However, on pooling adjusted risk estimates, the use of statin was found to significantly reduce the risk of adverse outcomes (OR 0.51; 95% CI 0.41 to 0.63, p<0.0005, I2=0%, fixed-effects model). Statin use is associated with improved clinical outcomes in patients with COVID-19. Individuals with multiple comorbidities on statin therapy should be encouraged to continue the drug amid the ongoing pandemic. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Report this publication

Statistics

Seen <100 times